Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Illinois court rules in GSK's favour in Zantac case

(Sharecast News) - GSK was upbeat after securing a legal victory in a case in the ongoing litigation surrounding its discontinued heartburn drug Zantac.

The FTSE 100 pharmaceuticals giant said a jury in an Illinois state court ruled in its favour, finding it not liable for a plaintiff's colorectal cancer.

It said the verdict aligned with the prevailing scientific consensus, which held that there was no consistent or reliable evidence linking the active ingredient ranitidine to an increased risk of cancer.

The company emphasised that the decision was backed by 16 epidemiological studies that had examined the potential health impacts of ranitidine.

GSK reiterated its commitment to vigorously defending itself against the remaining claims related to the Zantac.

The company also noted that the court had previously dismissed the plaintiff's request for punitive damages, further strengthening GSK's position in the legal battle.

At 0804 BST, shares in GSK were up 0.42% at 1,554p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Tesco, Sainsbury's slide as Asda says overhaul will dent profits
(Sharecast News) - UK supermarket stocks tumbled on Friday after Asda said it would undertake a "substantive" programme of investment in price, availability and the shopping experience to get the business "firing on all cylinders again" that will "materially" dent its profits.
KKR, Stonepeak bid deadline for Assura extended
(Sharecast News) - Assura said on Friday that the deadline by which investment firms KKR and Stonepeak must announce a firm offer for the group has been extended to allow the consortium more time for due diligence.
Bakkavor shares soar as £1.13bn Greencore bid rejected
(Sharecast News) - Shares in Bakkavor surged late on Friday as it emerged the food company rejected two bids from UK rival Greencore - the second worth £1.13bn.
Travis Perkins delays FY results; shares slide again
(Sharecast News) - Travis Perkins said on Friday that its results for the year to the end of December 2024 will be delayed as its auditor has requested additional time to complete standard audit procedures, sending shares in the builders' merchant tumbling for the second time this week.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.